Related Experiment Video
Updated: Jun 23, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Current approaches to renovascular hypertension
1Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, USA. textor.stephen@mayo.edu
Abstract:
This article examines the status regarding prevalence, mechanisms, clinical manifestations and management of renovascular hypertension at this point in time. It should be viewed as a work in progress. As with most complex conditions, clinicians must integrate the results of published literature studies while considering each patient's specific features and comorbid disease risks. Beyond identifying renovascular disease as a cause of secondary hypertension, one must manage renal artery stenosis (RAS) itself as an atherosclerotic vascular complication. This disease warrants follow-up regarding progression and potential for ischemic tissue injury. These elements often determine the role and timing for revascularization. In this respect, atherosclerotic renal artery stenosis is analogous to progressive carotid or aortic aneurysmal disease.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Direct Renin Inhibitors
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hypertension and Regulation of Blood Pressure
Hypertension III: Clinical Manifestations and Diagnostic Studies
Antihypertensive Drugs: Vasodilators
